Month: April 2020

Ny bestyrelsesformand og næstformandGeneralforsamlingen i A/S Øresundsforbindelsen besluttede den 17. april 2020 at indsætte Mikkel Hemmingsen som nyt bestyrelsesmedlem samt bestyrelsesformand i A/S Øresundsforbindelsen. Generalforsamlingen besluttede også at indsætte Louise Friis som nyt medlem af bestyrelsen samt næstformand i A/S Øresundsforbindelsen. Endeligt blev det besluttet, at Mogens Hansen indtræder som nyt medlem af bestyrelsen i A/S Øresundsforbindelsen.Den nuværende bestyrelse fratræder som bestyrelsesmedlemmer i A/S Øresundsforbindelsen, herunder Peter Frederiksen som formand og Jørn Tolstrup Rohde som næstformand.CV med baggrundsoplysninger om de valgte kandidater er vedlagt denne meddelelse.Ny administrerende direktørIdet Mikkel Hemmingsen er valgt som ny bestyrelsesformand fratræder han som administrerende direktør i...

BURNABY, British Columbia, April 17, 2020 (GLOBE NEWSWIRE) — Mobetize Corp. (OTC:MPAY) today announced that its Board of Directors has approved a dividend of one hundred percent (100%) of the outstanding shares of its wholly owned subsidiary Mobetize Canada, Inc. to Mobetize Corp. stockholders (“Dividend”). The Dividend will be payable at the open of business on May 1, 2020, to Mobetize Corp. stockholders at the close of business on March 31, 2020 (“Dividend Date”). The Dividend is part of a restructuring plan to consolidate the focus of its business on Mobetize Canada, Inc. in an effort to build stockholder value by improving the allocation of available capital.Stockholders of Mobetize Corp. are entitled to receive the Dividend pro rata that provides for one (1) share of Mobetize Canada, Inc.’s common stock for every one (1) share...

TORONTO, April 17, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has engaged Complete Phytochemical Solutions, LLC., an internationally-recognized company specializing in unique and complex analyses and formulation development of phytochemicals, to advance the Company’s research and development initiatives of psilocybin-based products for the pharmaceutical market.“Revive has an intellectual property portfolio of psilocybin-based formulations ready to advance to the next stages of clinical development and with our newly-established relationship with Complete Phytochemical Solutions they will bring a wealth of product formulation and testing...

MELBOURNE, Australia, April 17, 2020 (GLOBE NEWSWIRE) — Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that a scientific paper describing the use of Cymerus™ mesenchymal stem cells (MSCs) in a model of Acute Respiratory Distress Syndrome (ARDS) has been accepted for publication in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).1 The AJRCCM, commonly known as “The Blue Journal”, is widely regarded as the foremost peer-reviewed journal in the field of respiratory and critical care medicine.BackgroundThe study was conducted in 14 sheep with severe ARDS supported by extracorporeal membrane oxygenation (ECMO), which were given an endobronchial infusion of either Cymerus MSCs (n=7) or placebo (n=7). Animals were monitored...

NEW YORK, April 17, 2020 (GLOBE NEWSWIRE) — Apollo Commercial Real Estate Finance, Inc. (the “Company” or “ARI”) (NYSE:ARI), today announced the Company will hold a conference call to review its first quarter 2020 financial results on Friday, May 8, 2020 at 9:00 a.m. Eastern Time.  The Company’s first quarter financial results will be released after the market closes on Thursday, May 7, 2020.  During the conference call, Company officers will review first quarter 2020 performance, discuss recent events and conduct a question-and-answer period.Teleconference Details:Members of the public who are interested in participating in the Company’s first quarter 2020 earnings teleconference call should dial from the U.S., (877) 331-6553, or from outside the U.S., (760) 666-3769, shortly before 9:00 a.m. and reference the Apollo Commercial...

NEW YORK, April 17, 2020 (GLOBE NEWSWIRE) — National General Holdings Corp. (NASDAQ:NGHC) announced today that it plans to release 2020 first quarter results after the market closes on Wednesday, April 29, 2020. At 9:00 AM ET on Thursday, April 30, 2020, Chief Executive Officer Barry Karfunkel and Chief Financial Officer Mike Weiner will review results and discuss business conditions via a conference call that may be accessed as follows:A replay of the conference call will be accessible from 2:00 PM ET on Thursday, April 30, 2020 to 11:59 PM ET on Thursday, May 14, 2020 by dialing either 800-332-6854 (toll-free) within the U.S. or 973-528-0005 outside the U.S. and entering passcode 929313. In addition, a replay of the webcast can also be retrieved at http://ir.nationalgeneral.com/events-and-presentations.About National General Holdings...

SUWON, Republic of Korea, April 17, 2020 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a key player in the development of RNAi therapeutics, today announced the appointment of Dr. Gordon Jiang, Dr. Aaron Hakim and Dr. Yury V. Popov to its Scientific Advisory Board (SAB). The SAB will work with OliX Pharmaceuticals executive team to refine the emerging pipeline as well as clinical strategy for the company’s assets.“We are pleased to welcome Dr. Jiang, Dr. Hakim and Dr. Popov, renowned liver disease experts, to OliX Pharmaceuticals’ Scientific Advisory Board,” said Dong-Ki Lee, Ph.D., founder and Chief Executive Officer of OliX Pharmaceuticals. “Their depth of scientific expertise will be critical as we enter a pivotal phase in advancing the Company’s liver fibrosis pipeline.”Backgrounds of Newly Appointed Scientific...

ST. LOUIS, April 17, 2020 (GLOBE NEWSWIRE) — A new Stifel Financial Corp. (NYSE: SF) survey of nearly 300 technology executives, entrepreneurs, and private equity (PE) and venture capital (VC) investors finds most expect the COVID-19 crisis to have a lengthy impact on business operations, leading to a U-shaped economic recession. At the same time, the survey indicates that a majority of companies appear to have sufficient liquidity to weather the storm and potentially eye add-on acquisitions.Key survey highlights include:The majority of PE/VC respondents (62%) expect to see a business impact from COVID-19 on their portfolio companies for more than six months, while nearly half of tech executives/entrepreneurs (46%) are also planning for disruption lasting at least half a year. Most (55% of executives/entrepreneurs and 65% of PE/VC...

Orlando, Florida, April 17, 2020 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), operator of IZEAx®, the premier online marketplace connecting brands and publishers with influential content creators, today announced the launch of BrandGraph® Trends. BrandGraph Trends is designed to help marketers identify, compare and contrast momentum among brands, topics, and concepts in social media. Powered by IZEA’s proprietary content classification engine, BrandGraph Trends allows marketers to benchmark any keyword against a brand or groups of brands in a general industry or specific category.For example:Compare mentions of Coronavirus against content mentioning Purell.Compare content engagement rate of Purell against engagement rate of Lysol.Compare sentiment of Lysol against sentiment of all the brands in the household cleaner category.Compare...

 Receives valuation of Alzheimer’s disease blood diagnostic LymPro Test Retains Donohoe Advisors to assist with Nasdaq CM™ listing processREHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 17, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE —Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders as well as point-of-care and lab-based tests for COVID-19, announces the appointment of Lauren Chung, Ph.D. to its Board of Directors. This appointment increases the size of the Todos Medical Board to 7 Directors, including 2 independent Directors.  Dr. Chung has been named lead independent Director, and will serve as Chair of both the Compensation Committee and the Nomination and Governance Committee.Todos Medical...